MedPath

Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

Phase 3
Completed
Conditions
Chronic Schizophrenia
Interventions
Registration Number
NCT00789698
Lead Sponsor
Sumitomo Pharma America, Inc.
Brief Summary

Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR long term among schizophrenic outpatients with chronic schizophrenia.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
240
Inclusion Criteria
  • Completed all required assessments on the final study visit in Study D1050233.
  • Suitable for treatment in an outpatient setting.
Exclusion Criteria
  • Any chronic organic disease of the CNS (other than schizophrenia).
  • Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
QuetiapineQuetiapine XR-
Lurasidone HC1Lurasidone HC1-
Primary Outcome Measures
NameTimeMethod
Relapse of Psychotic Symptoms12 Months

Time to relapse will be defined as the earliest occurrence of any of the following:

* Worsening of \>= 30% positive and negative syndrome scale total score from NCT00790192 and clinical global impression-severity sub-scale \>=3

* rehospitalization for worsening of psychosis

* emergence of suicidal ideation, homicidal ideation and/or risk of harm to self or others Comparison of time to relapse of psychotic symptoms between lurasidone and quetiapine XR after 1 year as analyzed using the Cox proportional hazard model with country as a covariate.

Secondary Outcome Measures
NameTimeMethod
Change From the Acute Phase Baseline to Month 6 of the Double-blind Treatment in the CogState Computerized Cognitive Scores.Baseline and 6 Months

The battery has seven outcome measures that measure the cognitive constructs. The seven domains are: detection, identification, one back task, international shopping list task, one card learning task, Groton maze learning task and social emotional matching. The standardized scores for each subject at each assessment will then be averaged to yield a composite score. There are no maximum or minimum values, however a higher score indicates improved performance on the cognitive constructs. The change score is change from baseline to month 6.

Change From the Acute Phase Baseline to the End (Month 12) of the Double-blind Treatment in the Clinical Global Impression Severity Scale (CGI-S) ScoresBaseline and 12 months

The CGI-S is a clinician-rated assessment of the subject's current illness state on a scale ranging from 1-7, where a higher score is associated with greater illness severity.

Change From the Acute Phase Baseline to the End (Month 12) of the Double-blind Treatment in the Positive and Negative Syndrome Scale (PANSS)Baseline and 12 months

The PANSS is an interview-based measure of psychopathology severity in adults with psychotic disorders. Thirty items are rated using a Likert scale, from 1 - 7. The PANSS total score is the sum of thirty items ranging from 30 to 210 (higher score representing a worsening in psychosis).

Trial Locations

Locations (62)

Florida Clinical Research Center LLC

🇺🇸

Bradenton, Florida, United States

Pillar Clinical Research

🇺🇸

Dallas, Texas, United States

Deenanath Mangeshkar Hospital and Research Centre

🇮🇳

Pune, Maharastra, India

Spitalul Judetean Arges

🇷🇴

Pitesti, Romania

City Psychoneurological Dispensary #7 (with Hospital)

🇷🇺

St-Petersburg, Russian Federation

Crimean republican Clinical Psychiatric Hospital

🇺🇦

Simferopol, Ukraine

Kherson Regional Psychiatric Hospital

🇺🇦

vil. Stepanovka, Kherson, Ukraine

Comprehensive Neuroscience, Inc.

🇺🇸

Washington, District of Columbia, United States

Kyiv City Psychoneurological Hospital

🇺🇦

Kyviv, Ukraine

Vijayawada Institute of Mental Health and Neurosciences

🇮🇳

Vijayawada, Andhra Pradesh, India

Centro de Investigacion y Atencion para la Salud Mental

🇨🇴

Calle 103A # 21-49, Bogota S/N, Colombia

Andreev, Boris

🇷🇺

Gatchina, Russian Federation

CRI Worldwide

🇺🇸

Willingboro, New Jersey, United States

Madras Medical College & Government General Hospital

🇮🇳

Chennai, TamilNadu, India

Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340

🇺🇸

Lake Charles, Louisiana, United States

CIPNA Centro de Investigaciones y Proyectos en Neurociencias

🇨🇴

Calle 80#47-43 Consultorio 5C, Barranquila S/N, Colombia

S.V. Medical College

🇮🇳

Tirupati, Andra Pradesh, India

JSS Medical College and Hospital - Dept of Psychiatry

🇮🇳

Mysore, Karna, India

Spitalul Clinic Judetean de Urgenta Arad

🇷🇴

Str. Octavian Goga nr. 17, Arad, Romania

City Psychiatric Hospital #3 of Skvortsov-Stepanov

🇷🇺

St. Petersburg, Russian Federation

Gurovich, Isaak

🇷🇺

Moscow, Russian Federation

K&S Professional Research Services, LLC

🇺🇸

Little Rock, Arkansas, United States

Woodland International Research Group

🇺🇸

Little Rock, Arkansas, United States

Comprehensive Neuroscience, Inc

🇺🇸

Holliswood, New York, United States

Clinical Innovations, Inc.

🇺🇸

Riverside, California, United States

Synergy Escondido,710 East Grand Ave.

🇺🇸

Escondido, California, United States

Apostle Clinical Trials, Inc.

🇺🇸

Long Beach, California, United States

Pasadena Research Institute

🇺🇸

Pasadena, California, United States

California Clinical Trials

🇺🇸

Paramount, California, United States

CNRI - Los Angeles LLC,8309 Telegraph Road

🇺🇸

Pico Rivera, California, United States

CNRI- LOs Angeles, LLC

🇺🇸

Pico Rivera, California, United States

UCSD Medical Drive

🇺🇸

Sandeigo, California, United States

CNRI - San Diego

🇺🇸

San Diego, California, United States

Booker, J. Gary, MD. APMC

🇺🇸

Shreveport, Louisiana, United States

St. Charles Psychiatric Associates

🇺🇸

St. Charles, Missouri, United States

St. Louis Research, Inc.

🇺🇸

St. Louis, Missouri, United States

Community Clinical Research

🇺🇸

Austin, Texas, United States

FutureSearch Clinical Trials, LLC.

🇺🇸

Austin, Texas, United States

Centro de Investigaciones y Proyectos en Neurociencias CIPNA

🇨🇴

Barranquilla, Colombia

Centro de Investigación y Atención para la Salud Mental

🇨🇴

Bogota, Colombia

CISNE - UIC Campo Abierto

🇨🇴

Bogota, Colombia

Instituto Colombiano del Sistema Nervioso Clínica Montserrat

🇨🇴

Bogota, Colombia

Shanti Nursing Home

🇮🇳

Kanchanpalli, Aurangabad, Maharashtra, India

Seth K M School of P G Medicine & Research

🇮🇳

Ahmedabad, Gujarat, India

SBKS Medical College and Hospital, Brij Psychiatry Hospital

🇮🇳

Vadodara, Gujarat, India

Justice K.S. Hedge Charitable Hospital

🇮🇳

Mangalore, Karna, India

Mahatma Gandhi Institute of Medical Sciences

🇮🇳

Sewagram, Maharashtra, India

Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia

🇷🇴

Bucuresti, Romania

Spitalul Clinic de Neurologie si Psihiatrie Oradea

🇷🇴

Oradea, Romania

Morozova, Margarita

🇷🇺

Moscow, Russian Federation

Sheifer, Mikhail

🇷🇺

Samara, Russian Federation

City Psyhiatric Hospital #2 of St. Nikolay Chudotvorets

🇷🇺

St. Petersburg, Russian Federation

City Psychiatric Hospital #4

🇷🇺

St. Petersburg, Russian Federation

Neznanov, Nikolay

🇷🇺

St. Petersburg, Russian Federation

Dnipropetrovsk Regional Clinical Hospital named Mechnikov

🇺🇦

Dnipropetrovsk, Ukraine

Reg.Clin.Psychiatric Hosp., Dept. #11, DSMU n.af.M.Gorkiy

🇺🇦

Donetsk, Ukraine

Kyiv City Clin. Psychoneurolog. Hosp.#1

🇺🇦

Kyiv, Ukraine

Lviv Reg.St.Cl.Psych.Hosp

🇺🇦

Lviv, Ukraine

Reg. Psychiatric Hospital

🇺🇦

Odessa, Ukraine

SUNY Downstate Medical Center

🇺🇸

Brooklyn, New York, United States

Segal Institute for Clinical Research

🇺🇸

Highlands Ranch, Colorado, United States

Collaborative Neuroscience Network Inc

🇺🇸

Garden Grove, California, United States

© Copyright 2025. All Rights Reserved by MedPath